UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ________ Commission File Number: 001-34079 Ocuphire Pharma, Inc. (Exact name of Registrant as specified in its charter) Delaware 11-3516358 (State or Other Juris ...

FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) – Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. "Ocuphire has made significant progress in 2024, with important developments for both APX3330 and RYZUMVI™," said George Magrath, M. ...

FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. "Ocuphire has made significant progress in 2024, with important developments for both APX3330 and RYZUMVI™," said George Magrath, M. ...

FARMINGTON HILLS, Mich., May 03, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A., M.S., Chief Executive Officer of Ocuphire, will present a company overview at the Aegis Virtual Conference being held May 7-9, 2024. Company management will also be participating in one-on-one meetings throughout the conference ...

FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the Fiscal Year Ended December 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from _____ to _____ Commission File No. 001-34079 Ocuphire Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3516358 (State or other jurisdiction of i ...

FARMINGTON HILLS, Mich., March 8, 2024 (GLOBE NEWSWIRE) – Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. "Ocuphire had a successful 2023, with notable achievements on the regulatory and development fronts, paving the way fo ...

Ocuphire Pharma, Inc. Corporate Update Call Summary Company Overview - **Company**: Ocuphire Pharma, Inc. (NASDAQ: OCUP) - **Date of Call**: December 5, 2023 - **Participants**: - Dr. George Magrath - CEO - Michael Wood - LifeSci Advisors - Charlie Hoffmann - SVP of Corporate Development - Ronil Patel - Chief Business Officer Key Points Industry and Company Focus - Ocuphire is focused on the ophthalmology sector, particularly in developing treatments for diabetic retinopathy, which is a leading cause of blindness in working-age Americans [9][12][14]. - The company has two main ophthalmic assets, with a strong emphasis on APX3330, an oral treatment for non-proliferative diabetic retinopathy [10][11]. Leadership and Strategy - Dr. George Magrath, the newly appointed CEO, has extensive experience in ophthalmology and drug development, previously leading Lexitas Pharma Services [6][8]. - The immediate priority is to develop and implement a strategy to advance Ocuphire's assets, particularly APX3330, towards commercialization [10][18]. Product Development and Clinical Trials - APX3330 has shown promise in treating diabetic retinopathy and is expected to enter Phase 3 trials in the second half of 2024 [15][17]. - The FDA has agreed on the primary endpoint for the Phase 3 trials, focusing on a three-step worsening on a binocular diabetic retinopathy severity scale [15][34]. - The company aims to address the significant market of approximately 8 million patients in the U.S. with progressive diabetic retinopathy who are currently asymptomatic [14][25]. Market Opportunity - There is a compelling commercial opportunity for APX3330, as current treatments involve invasive injections that many patients are reluctant to receive [14][20]. - The oral formulation of APX3330 is expected to be well-received due to its convenience compared to intravitreal injections [21][23]. Financial Position - As of September 30, 2023, Ocuphire reported over $42 million in cash and no debt, with a $10 million milestone payment received from Viatris [17]. - The company anticipates that its current financial position will support operations into 2025 while exploring additional financing options for further development [17]. Management and Team Development - The company is in the process of filling key management positions, including a Chief Medical Officer and a Chief Financial Officer, to strengthen its leadership team [16][18]. Future Outlook - Ocuphire is committed to advancing its pipeline and engaging with the investment community to provide updates on its progress [18][40]. - The strategic focus includes not only the development of APX3330 but also potential partnerships with large pharmaceutical companies interested in the product [17][31]. Additional Insights - The company is exploring the potential systemic benefits of APX3330 beyond ophthalmology, considering its implications for broader diabetic complications [28][31]. - Market research indicates a favorable reception for oral therapies in ophthalmology, as evidenced by the acceptance of AREDS vitamins among patients with intermediate dry AMD [24][25]. This summary encapsulates the critical insights and strategic direction of Ocuphire Pharma as discussed during the corporate update call.

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ________ Commission File Number: 001-34079 Ocuphire Pharma, Inc. (Exact name of Registrant as specified in its charter) Delaware 11-3516358 (State or Other J ...

Washington, DC 20549 Form 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ________ Commission File Number: 001-34079 Ocuphire Pharma, Inc. (Exact name of Registrant as specified in its charter) Delaware 11-3516358 (State or Other Jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 Delaware 11-3516358 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 37000 Grand River Avenue, Suite 120 (Address of Principal Executive Offi ...